发布求助
文献互助 智能选刊 最新文献

CNS Oncology最新文献

筛选
英文 中文
Development of brain metastases in non-small-cell lung cancer: high-risk features. 非小细胞肺癌脑转移的发展：高风险特征。
CNS Oncology Pub Date : 2024-12-31 Epub Date: 2024-09-12 DOI: 10.1080/20450907.2024.2395804
Nolan Winslow, Jacqueline Boyle, William Miller, Yanzhi Wang, Francois Geoffroy, Andrew J Tsung
{"title":"Development of brain metastases in non-small-cell lung cancer: high-risk features.","authors":"Nolan Winslow, Jacqueline Boyle, William Miller, Yanzhi Wang, Francois Geoffroy, Andrew J Tsung","doi":"10.1080/20450907.2024.2395804","DOIUrl":"https://doi.org/10.1080/20450907.2024.2395804","url":null,"abstract":"<p><p><b>Aim:</b> Brain metastases (BM) are a common site of disease progression and treatment failure in non-small-cell lung cancer (NSCLC) and can be identified in up to 30-50% of patients. Although they are common, there is no standardized screening protocol for development of BM in NSCLC. Multiple clinical variables predict increased BM occurrence, and, when present, should be used to initiate screening MRI.<b>Materials & methods:</b> We performed a single center retrospective review of NSCLC patients, examining BM development and overall survival. Available clinical, radiographic and molecular data were reviewed for association with BM and overall survival. A predictive model for BM development was created for multivariate analysis.<b>Results:</b> Risk factors for new BM development in NSCLC included younger age, larger primary lung tumor, Karnofsky performance score (KPS) <70, pre-existing liver or bone metastases, large cell histology and family history of cancer. Factors associated with decreased OS were larger primary lung tumor, extracranial metastases at time of diagnosis, large cell histology and poorly-differentiated carcinoma histology.<b>Conclusion:</b> There are multiple high risk features for developing BM in NSCLC. Each of these factors should routinely be investigated, and presence should prompt brain MRI to allow earlier diagnosis and treatment of BM.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"13 1","pages":"2395804"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11404603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autologous stem cell transplantation in adults with atypical teratoid rhabdoid tumor: a case report and review. 成人非典型畸胎性横纹肌瘤患者的自体干细胞移植：病例报告与综述。
CNS Oncology Pub Date : 2024-12-31 Epub Date: 2024-07-23 DOI: 10.1080/20450907.2024.2375960
Jackson Griffith-Linsley, William Robert Bell, Aaron Cohen-Gadol, Diane Donegan, Angela Richardson, Michael Robertson, Kevin Shiue, Kathryn Nevel
{"title":"Autologous stem cell transplantation in adults with atypical teratoid rhabdoid tumor: a case report and review.","authors":"Jackson Griffith-Linsley, William Robert Bell, Aaron Cohen-Gadol, Diane Donegan, Angela Richardson, Michael Robertson, Kevin Shiue, Kathryn Nevel","doi":"10.1080/20450907.2024.2375960","DOIUrl":"10.1080/20450907.2024.2375960","url":null,"abstract":"<p><p><b>Aim:</b> Atypical teratoid rhabdoid tumor (ATRT) is a rare and highly aggressive primary CNS neoplasm, predominantly observed in children. The use of autologous stem cell transplantation (ASCT) in pediatric ATRT has shown promise; however, its utility in adult ATRT remains unclear. <b>Patients & methods:</b> This study presents the case of an adult patient with ATRT who is in remission after ASCT and reviews the literature on ASCT in adults with ATRT. Four cases of ATRT in adults who underwent ASCT were identified, with pertinent data summarized. <b>Results:</b> All five patients survived longer than the historical average survival rate, four of whom had no clinical or radiographic evidence of disease at the final follow-up. <b>Conclusion:</b> Based on limited data, there may be a role for ASCT in the treatment of adults with ATRT.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"13 1","pages":"2375960"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11285279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radio-pathomic estimates of cellular growth kinetics predict survival in recurrent glioblastoma. 细胞生长动力学的放射病理估算可预测复发性胶质母细胞瘤的存活率。
CNS Oncology Pub Date : 2024-12-31 Epub Date: 2024-11-13 DOI: 10.1080/20450907.2024.2415285
Sonoko Oshima, Jingwen Yao, Samuel Bobholz, Raksha Nagaraj, Catalina Raymond, Ashley Teraishi, Anna-Marie Guenther, Asher Kim, Francesco Sanvito, Nicholas S Cho, Blaine S. C. Eldred, Jennifer M Connelly, Phioanh L Nghiemphu, Albert Lai, Noriko Salamon, Timothy F Cloughesy, Peter S LaViolette, Benjamin M Ellingson
{"title":"Radio-pathomic estimates of cellular growth kinetics predict survival in recurrent glioblastoma.","authors":"Sonoko Oshima, Jingwen Yao, Samuel Bobholz, Raksha Nagaraj, Catalina Raymond, Ashley Teraishi, Anna-Marie Guenther, Asher Kim, Francesco Sanvito, Nicholas S Cho, Blaine S. C. Eldred, Jennifer M Connelly, Phioanh L Nghiemphu, Albert Lai, Noriko Salamon, Timothy F Cloughesy, Peter S LaViolette, Benjamin M Ellingson","doi":"10.1080/20450907.2024.2415285","DOIUrl":"10.1080/20450907.2024.2415285","url":null,"abstract":"<p><p><b>Aim:</b> A radio-pathomic machine learning (ML) model has been developed to estimate tumor cell density, cytoplasm density (Cyt) and extracellular fluid density (ECF) from multimodal MR images and autopsy pathology. In this multicenter study, we implemented this model to test its ability to predict survival in patients with recurrent glioblastoma (rGBM) treated with chemotherapy.<b>Methods:</b> Pre- and post-contrast T<sub>1</sub>-weighted, FLAIR and ADC images were used to generate radio-pathomic maps for 51 patients with longitudinal pre- and post-treatment scans. Univariate and multivariate Cox regression analyses were used to test the influence of contrast-enhancing tumor volume, total cellularity, mean Cyt and mean ECF at baseline, immediately post-treatment and the pre- and post-treatment rate of change in volume and cellularity on overall survival (OS).<b>Results:</b> Smaller Cyt and larger ECF after treatment were significant predictors of OS, independent of tumor volume and other clinical prognostic factors (HR = 3.23 × 10<sup>-6</sup>, p < 0.001 and HR = 2.39 × 10<sup>5</sup>, p < 0.001, respectively). Both post-treatment volumetric growth rate and the rate of change in cellularity were significantly correlated with OS (HR = 1.17, p = 0.003 and HR = 1.14, p = 0.01, respectively).<b>Conclusion:</b> Changes in histological characteristics estimated from a radio-pathomic ML model are a promising tool for evaluating treatment response and predicting outcome in rGBM.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"13 1","pages":"2415285"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neurofilament light chain in serum of cancer patients with acute neurological complications. 患有急性神经并发症的癌症患者血清中的神经丝蛋白轻链。
CNS Oncology Pub Date : 2024-12-31 Epub Date: 2024-08-13 DOI: 10.1080/20450907.2024.2386233
Amulya Gottiparthy, Keng Lam, Suprateek Kundu, Zixi Yang, Ivo Tremont-Lukats, Sudhakar Tummala
{"title":"Neurofilament light chain in serum of cancer patients with acute neurological complications.","authors":"Amulya Gottiparthy, Keng Lam, Suprateek Kundu, Zixi Yang, Ivo Tremont-Lukats, Sudhakar Tummala","doi":"10.1080/20450907.2024.2386233","DOIUrl":"10.1080/20450907.2024.2386233","url":null,"abstract":"<p><p><b>Aim:</b> Neurofilament light chain (NfL) is a nonspecific sensitive biomarker of axonal damage.<b>Methods:</b> This case series identified cancer patients with neurological complications who had serum NfL measurements and paired these results to outcomes.<b>Results:</b> NfL serum levels were available in 15 patients with hematological malignancies or solid tumors. The neurological complications studied were immune effector cell-associated neurotoxicity syndrome, immune checkpoint inhibitor-related encephalopathy, anoxic brain injury, Guillain-Barre syndrome, hemophagocytic lymphohistiocytosis, transverse myelitis, paraneoplastic syndrome, central nervous system demyelinating disorder and chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. All patients but one with serum NfL >900 pg/ml died during hospitalization.<b>Conclusion:</b> Serum NfL levels consistently corresponded to death, disease severity or recovery in this series.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"13 1","pages":"2386233"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11323868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970811","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel insights toward diagnosis and treatment of glioneuronal and neuronal tumors in young adults. 诊断和治疗青壮年胶质细胞瘤和神经元肿瘤的新见解。
CNS Oncology Pub Date : 2024-12-31 Epub Date: 2024-06-14 DOI: 10.1080/20450907.2024.2357532
Vincenzo Di Nunno, Marta Aprile, Lidia Gatto, Alicia Tosoni, Lucia Ranieri, Stefania Bartolini, Enrico Franceschi
{"title":"Novel insights toward diagnosis and treatment of glioneuronal and neuronal tumors in young adults.","authors":"Vincenzo Di Nunno, Marta Aprile, Lidia Gatto, Alicia Tosoni, Lucia Ranieri, Stefania Bartolini, Enrico Franceschi","doi":"10.1080/20450907.2024.2357532","DOIUrl":"10.1080/20450907.2024.2357532","url":null,"abstract":"<p><p><b>Aim:</b> Glioneuronal and neuronal tumors are rare primary central nervous system malignancies with heterogeneous features. Due to the rarity of these malignancies diagnosis and treatment remains a clinical challenge. <b>Methods:</b> Here we performed a narrative review aimed to investigate the principal issues concerning the diagnosis, pathology, and clinical management of glioneuronal tumors. <b>Results:</b> Diagnostic criteria have been recently overturned thanks to a better characterization on a histological and molecular biology level. The study of genomic alterations occurring within these tumors has allowed us to identify potential therapeutic targets including BRAF, FGFR, and PDGFRA. <b>Conclusion:</b> Techniques allowing molecular sequencing DNA methylation assessment of the disease are essential diagnostic tools. Targeting agents should be included in the therapeutic armamentarium after loco-regional treatment failure.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"13 1","pages":"2357532"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complete resection of a giant epidermoid cyst of the occipital bone: case report and systematic review. 完全切除枕骨巨大表皮样囊肿：病例报告和系统综述。
CNS Oncology Pub Date : 2024-12-31 Epub Date: 2024-11-19 DOI: 10.1080/20450907.2024.2415279
Ishwarya Nair, Adrian Zammit, Timothy Williamson, Ananthababu Pattavilakom Sadasivan
{"title":"Complete resection of a giant epidermoid cyst of the occipital bone: case report and systematic review.","authors":"Ishwarya Nair, Adrian Zammit, Timothy Williamson, Ananthababu Pattavilakom Sadasivan","doi":"10.1080/20450907.2024.2415279","DOIUrl":"10.1080/20450907.2024.2415279","url":null,"abstract":"<p><p>Epidermoid cysts are uncommon accounting for less than 1% of all intracranial tumors. Among them, giant intradiploic epidermoid cysts of the posterior fossa i.e. those exceeding 5 cm are an even rarer entity. Here we report on the complete resection of a 7 cm posterior fossa epidermoid cyst involving the occipital bone in a 32-year-old female presenting with an acute on chronic exacerbation of headaches and vertigo. Complete resection including the cyst wall is crucial in preventing recurrence and malignant transformation. We add to limited existing data by reporting on the first systematic review to date assessing 25 cases of giant epidermoid cysts of the posterior fossa to discuss presentation, clinical and radiographic features and definitive management strategies.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"13 1","pages":"2415279"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The challenges and clinical landscape of glioblastoma immunotherapy. 胶质母细胞瘤免疫疗法面临的挑战和临床前景。
CNS Oncology Pub Date : 2024-12-31 Epub Date: 2024-10-29 DOI: 10.1080/20450907.2024.2415878
Andrew Timothy Ng, Tyler Steve, Kevin T Jamouss, Abdul Arham, Sarah Kawtharani, Hazem I Assi
{"title":"The challenges and clinical landscape of glioblastoma immunotherapy.","authors":"Andrew Timothy Ng, Tyler Steve, Kevin T Jamouss, Abdul Arham, Sarah Kawtharani, Hazem I Assi","doi":"10.1080/20450907.2024.2415878","DOIUrl":"10.1080/20450907.2024.2415878","url":null,"abstract":"<p><p>Glioblastoma is associated with a dismal prognosis with the standard of care involving surgery, radiation therapy and temozolomide chemotherapy. This review investigates the features that make glioblastoma difficult to treat and the results of glioblastoma immunotherapy clinical trials so far. There have been over a hundred clinical trials involving immunotherapy in glioblastoma. We report the survival-related outcomes of every Phase III glioblastoma immunotherapy trial with online published results we could find at the time of writing. To date, the DCVax-L vaccine is the only immunotherapy shown to have statistically significant increased median survival compared with standard-of-care in a Phase III trial: 19.3 months versus 16.5 months. However, this trial used an external control group to compare with the intervention which limits its quality of evidence. In conclusion, glioblastoma immunotherapy requires further investigation to determine its significance in improving disease survival.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"13 1","pages":"2415878"},"PeriodicalIF":0.0,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524205/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142521216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prolonged remission with ibrutinib maintenance therapy following radiation in a patient with relapsed primary CNS lymphoma. 一名原发性中枢神经系统淋巴瘤复发患者在接受伊布替尼放射治疗后，通过伊布替尼维持治疗延长了缓解期。
CNS Oncology Pub Date : 2024-06-06 Epub Date: 2024-05-09 DOI: 10.1080/20450907.2024.2345579
Steven Du, Dan Beverly Fu, Daniela A Bota, Xiao-Tang Kong
{"title":"Prolonged remission with ibrutinib maintenance therapy following radiation in a patient with relapsed primary CNS lymphoma.","authors":"Steven Du, Dan Beverly Fu, Daniela A Bota, Xiao-Tang Kong","doi":"10.1080/20450907.2024.2345579","DOIUrl":"10.1080/20450907.2024.2345579","url":null,"abstract":"<p><p><b>Background:</b> Treatment for refractory or relapsed primary CNS lymphoma (r/r PCNSL) is challenging. Salvage whole-brain radiation therapy (WBRT) is an option but has a short duration of disease control, so additional treatment modalities are warranted. <b>Case:</b> A 75-year-old female with r/r PCNSL who had multiple progressions after multiple lines of treatment underwent salvage WBRT. The patient received ibrutinib, a Bruton's tyrosine kinase inhibitor, as maintenance therapy for 18 months following WBRT with the intention of increasing survival duration after salvage WBRT. She survived 81 months from diagnosis, including 57 months after completion of WBRT. <b>Conclusion:</b> This case presentation describes the experience of using ibrutinib as maintenance therapy in treating r/r PCNSL after salvage WBRT.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":" ","pages":"2345579"},"PeriodicalIF":0.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11137789/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140897590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perspectives from neuro-oncology providers on patient access to electronic records: a survey study. 神经肿瘤科医生对患者访问电子病历的看法：一项调查研究。
CNS Oncology Pub Date : 2024-06-06 Epub Date: 2024-05-28 DOI: 10.1080/20450907.2024.2352414
Keng Lam, Cheuk Hong Leung, Zaid Soomro, Chetna Wathoo, Shiao-Pei Weathers
{"title":"Perspectives from neuro-oncology providers on patient access to electronic records: a survey study.","authors":"Keng Lam, Cheuk Hong Leung, Zaid Soomro, Chetna Wathoo, Shiao-Pei Weathers","doi":"10.1080/20450907.2024.2352414","DOIUrl":"10.1080/20450907.2024.2352414","url":null,"abstract":"<p><p><b>Aim:</b> To evaluate the neuro-oncology providers' experience with patient online access to electronic records. <b>Methods:</b> Cross-sectional survey for physicians and advanced care providers within the field of neuro-oncology in the USA. <b>Results:</b> 65 providers completed the survey, from all major regions of the USA. 58% reported that at least once per month, patients contacted them outside of an office visit about provider notes or a laboratory or imaging finding accessed online. 54% of providers did not think that all laboratory results should be released automatically, and only 25% of providers thought that all radiology reads should be released immediately. 97% thought that some patients suffered substantial distress viewing test results prior to appointments. Qualitative responses aligned with the quantitative results. <b>Conclusion:</b> Most neuro-oncology providers are concerned about the immediate release of laboratory and imaging findings to patients without guidance.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"13 1","pages":"2352414"},"PeriodicalIF":0.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11152585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141310228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extracavitary primary effusion lymphoma presenting as a solitary brain mass. 表现为单发脑肿块的腔外原发性渗出淋巴瘤。
CNS Oncology Pub Date : 2024-06-06 Epub Date: 2024-06-12 DOI: 10.1080/20450907.2024.2357535
Tiffany Javadi, Bryan Morales, Jeffery J Olson, Shawn Kothari, Linsheng Zhang, Malak Abedalthagafi
{"title":"Extracavitary primary effusion lymphoma presenting as a solitary brain mass.","authors":"Tiffany Javadi, Bryan Morales, Jeffery J Olson, Shawn Kothari, Linsheng Zhang, Malak Abedalthagafi","doi":"10.1080/20450907.2024.2357535","DOIUrl":"10.1080/20450907.2024.2357535","url":null,"abstract":"<p><p>Primary effusion lymphoma (PEL) is an uncommon B-cell lymphoma associated with human herpesvirus 8 and comprises 3-4% of all HIV-related lymphomas. It traditionally presents as a pleural, pericardial, and/or peritoneal effusion, though it can occasionally manifest as an extracavitary or solid mass in the absence of an effusion. The extracavitary or solid variant of primary effusion lymphoma has been reported in the skin, gastrointestinal tract, lung, and lymph nodes. However, very few cases have been reported in the central nervous system. We describe a case of extracavitary or solid variant of primary effusion lymphoma presenting as a brain mass in an HIV-positive man, highlighting the clinicopathologic and immunophenotypic findings of a rare entity.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":"13 1","pages":"2357535"},"PeriodicalIF":0.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11172242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信